Stem cells and peptides: the double standard in how we judge them

Put the evidence for peptides and for unproven stem cell interventions side by side, and the peptide does not come off worse. Peptides face federal committee review and close votes. Stem cell packages sell on travel itineraries, with a longer published record of harm. The fair response is one standard for both: human evidence, product quality and traceability.

Key points

• In July 2026 the FDA devoted two days of committee meetings, one technical document per molecule and votes to seven peptides; BPC-157 and TB-500 passed 8 to 6 [3][4].
• In Panama, at least six companies were selling stem cell packages at the end of 2025, all including hotel, transport and tourist activities [6].
• According to the FDA (April 2024), the only stem cell products approved in the US were umbilical cord blood hematopoietic progenitors for blood disorders; in December 2024 a mesenchymal therapy for pediatric GVHD was added [10][11].
• Unproven stem cell interventions have published harms: blindness, a spinal cord glioproliferative lesion and infections requiring hospitalization [12][13][14].
• For BPC-157, a 2025 systematic review found no human clinical safety data, good or bad. The fair approach is one yardstick for both: evidence, quality and traceability [5][18].

US status (October 2026): BPC-157 is not FDA-approved and has no lawful compounding pathway, and MDside providers do not prescribe it. See the BPC-157 status page and the peptide status tracker.

Two patients get two different conversations

One patient tells you he injects a peptide bought online. Another tells you she traveled to a clinic to receive umbilical cord cells at a premium price. In most practices, the first gets the lecture. The second usually gets a curious question about whether it worked.

Peptides face more scrutiny than cells

In July 2026, the FDA Pharmacy Compounding Advisory Committee devoted two days of meetings to seven peptides, with an agency technical document for each one [3]. The votes were close: 8 to 6 for BPC-157, KPV and TB-500, and 7 to 5 for MOTS-c. None of that is approval or demonstrated clinical benefit [4]. The FDA also keeps BPC-157 on its list of substances that may present significant safety risks, citing possible immunogenicity and impurities [5]. The detail is in what the FDA actually said.

Stem cells have had a different path. In 2016 an analysis in Cell Stem Cell documented widespread promotion of unapproved interventions by US businesses [17]. By March 2021 there were 1,480 businesses operating 2,754 clinics, more than four times the number identified five years earlier [16].

Panama shows the same pattern abroad. Authors from the Gorgas Institute and the National Research Bioethics Committee (CNBI) counted at least six companies at the end of 2025. All of them offered packages bundling procedures, hotel, transport and tourist activities, promoted on Instagram, YouTube and Facebook [6]. The CNBI sent at least six notifications to the Ministry of Health between 2015 and 2025. The authors concluded: “The lack of enforcement by regulatory bodies has probably facilitated the growth of this unproven industry in Panama” [6].

• 8 to 6: FDA committee vote for BPC-157 and TB-500 [4]
• 1,480: US businesses selling unapproved stem cells in 2021 [16]
• 6: companies selling stem cell travel packages in Panama, end of 2025 [6]

Peptides have the stronger approval record

Since insulin, more than 80 peptide drugs have reached the market [1]. Semaglutide, a peptide, was associated in SELECT with a 20% reduction in the composite of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke in 17,604 adults with established cardiovascular disease and overweight or obesity but without diabetes (HR 0.80) [2]. More context is in the peptide universe.

On the cell side, the FDA sums it up itself. On its April 2024 page, the only stem cell products approved in the US were blood-forming cells derived from umbilical cord blood, approved only for disorders of the hematopoietic system [10]. Its official list includes nine cord blood products [9]. In December 2024 the first mesenchymal stromal cell therapy was added, for steroid-refractory acute graft-versus-host disease in children [11].

The agency states that no regenerative therapy is approved for knee pain, autism, Parkinson’s disease, ALS or COPD, and warns: “if you are being charged for these products or offered these products outside of a clinical trial, you are likely being deceived and offered a product illegally” [10]. For the US enforcement picture, see exosomes and stem cell marketing.

Stem cells have the longer harm file

In the New England Journal of Medicine, three patients suffered severe bilateral vision loss after intravitreal injections of adipose-derived “stem cells” at a US clinic. After one year, their visual acuity ranged from 20/200 to no light perception [12]. The same journal published a glioproliferative lesion of the spinal cord as a complication of “stem-cell tourism” [13], in a patient who had received injections in China, Mexico and Argentina and whose lesion originated from the implanted cells [15].

In 2018 the CDC described 12 patients in Texas, Florida and Arizona with infections after receiving bacterially contaminated cord blood-derived products. All were hospitalized and none died [14]. A review from the same year compiled 35 cases of complications or death after unproven interventions, and its authors warn that the figure probably underestimates the problem [15]. In Panama, the CNBI warned in August 2026 of documented risks such as thromboembolism, fibrosis, cell growth with tumor potential, severe vision loss and deaths [7].

A 2025 systematic review of BPC-157 found no human clinical safety data [18]. That is silence, and silence is no certificate of safety: the FDA points to theoretical risks such as immunogenicity [5]. The most publicized event was RAADfest in 2025. Two women were hospitalized in critical condition, requiring intubation, after injections at a conference booth run by a physician without permission to practice in Nevada. Both recovered [19][21]. The Nevada Pharmacy Board could not determine the cause, because it was unable to test the product. In February 2026 it fined three people: a physician and a pharmacist without permission to practice in Nevada, and the group accused of mailing the peptides [21].

Neither file is reassuring. Only one of them causes panic.

Both sit in similar legal gray zones

In Panama, Executive Decree 179 of 2018 recognizes hematopoietic transplantation as the only application with proven evidence; any other use must take place within approved research protocols [6][8]. The National Directorate of Pharmacy and Drugs has not registered advanced therapy products with stem cells for other uses [7], and in 2026 the Ministry of Health inspected two establishments and opened administrative proceedings against them [8]. Law 419 classifies “marketing a product without sanitary registration” as a very serious offense [20]. The local detail is in stem cells in Panama and the physician’s legal map in Panama.

The US position on peptides is set out in are peptides legal. If the unregistered peptide vial and the off-protocol cell infusion sit in similar gray zones, the difference in how physicians react to them needs an explanation.

Four reasons the cell gets forgiven

What follows is opinion, not evidence. Four hypotheses:

• The aura of the self. “They are your own cells” sounds like natural medicine, even when the product has been processed, cultured or comes from someone else’s cord.
• The set design. Scrubs, an operating room, a marble reception desk: the hospital setting lends a legitimacy the product has not earned.
• Price as argument. What costs a great deal looks serious. What costs little looks suspicious. Behavioral economics is not pharmacology.
• Bad company. Peptides entered public conversation alongside the gym, the influencer and the online store. Stem cells arrived alongside the academic laboratory and bone marrow transplantation. Both deserve to be judged by their data, not by their friends.

Apply one yardstick to both

Do not lower the bar for peptides. Apply it evenly. Ask three questions of any product that goes into a patient:

1. What human evidence exists for this indication?
2. What guarantees the quality of this lot?
3. Can its origin be traced?

By that yardstick, much of the unapproved stem cell market struggles. The FDA warns of cross-contamination and of products not tested for infectious diseases [10], and the CDC notes that cord blood cannot be decontaminated after collection [14].

That is where peptides can do better. A peptide is a synthetic molecule of known sequence whose identity and purity can be verified in the laboratory, lot by lot. The documented problem is the product’s origin, as discussed in what is really in the vial and supplier diligence. A “research use only” label does not solve it: see why that label is no shield. The class has already shown, with more than 80 approved drugs, that it can pass the exam [1]. The full arguments of its supporters are in the other side. A single standard is no threat to peptides. It is their best opportunity.

The other side. Stem cell science is legitimate and saves lives. Hematopoietic transplantation is an established treatment, authorized in Panama at four centers [6], and in 2024 the FDA approved the first mesenchymal therapy for pediatric GVHD [11]. Mesenchymal cells are considered safe when tested in well-designed studies [15]; the problem is the clinic. Peptide skeptics would reply that the committee’s 8 to 6 is neither approval nor demonstrated benefit [4], that the absence of published harm with BPC-157 reflects the absence of human studies [18], and that someone else’s misconduct does not absolve one’s own. They are right about the last point. This article does not claim peptides are innocent. It claims the yardstick must be the same.

References

1. Muttenthaler M, et al. Trends in peptide drug discovery. Nat Rev Drug Discov. 2021;20(4):309-325. PMID 33536635. Link
2. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. PMID 37952131. Link
3. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Link
4. Jacobus N. FDA panel votes to loosen restrictions for four peptides. Pharmaceutical Executive. 24 July 2026. Link
5. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Link
6. Samaniego A. Células madre en Panamá: clínicas ofrecen tratamientos sin evidencia científica. La Prensa (Panamá). 24 de julio de 2026. Link
7. La Prensa (Panamá). Tumores, ceguera y muerte: alerta por terapias con células madre sin evidencia. 5 de agosto de 2026. Link
8. Samaniego A. Minsa abre investigación a locales que ofrecen tratamientos con células madre. La Prensa (Panamá). 31 de agosto de 2026. Link
9. U.S. Food and Drug Administration. Approved Cellular and Gene Therapy Products (content current as of 17 September 2026). Link
10. U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies. Updated 8 April 2024. Link
11. U.S. Food and Drug Administration. FDA approves remestemcel-L-rknd for steroid-refractory acute graft versus host disease in pediatric patients. 18 December 2024. Link
12. Kuriyan AE, et al. Vision loss after intravitreal injection of autologous “stem cells” for AMD. N Engl J Med. 2017;376(11):1047-1053. PMID 28296617. Link
13. Berkowitz AL, et al. Glioproliferative lesion of the spinal cord as a complication of “stem-cell tourism”. N Engl J Med. 2016;375(2):196-198. PMID 27331440. Link
14. Perkins KM, et al. Notes from the Field: Infections after receipt of bacterially contaminated umbilical cord blood-derived stem cell products for other than hematopoietic or immunologic reconstitution, United States, 2018. MMWR Morb Mortal Wkly Rep. 2018;67(50):1397-1399. Link
15. Bauer G, et al. Concise review: a comprehensive analysis of reported adverse events in patients receiving unproven stem cell-based interventions. Stem Cells Transl Med. 2018;7(9):676-685. PMID 30063299. Link
16. Turner L. The American stem cell sell in 2021: U.S. businesses selling unlicensed and unproven stem cell interventions. Cell Stem Cell. 2021;28(11):1891-1895. PMID 34739831. Link
17. Turner L, Knoepfler P. Selling stem cells in the USA: assessing the direct-to-consumer industry. Cell Stem Cell. 2016;19(2):154-157. PMID 27374789. Link
18. Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485-495. PMID 40756949. Link
19. Damon A. A Las Vegas festival promised ways to cheat death. Two attendees left fighting for their lives. ProPublica. 29 July 2025. Link
20. República de Panamá. Ley 419 de 1 de febrero de 2024, que regula los medicamentos y otros productos para la salud humana (texto vía vLex). Link
21. Damon A. Nevada regulators fine peptide providers at anti-aging festival where two women became critically ill. ProPublica. 13 March 2026. Link

This is general information, not medical or legal advice. Rules vary by state and change. Confirm your own facts with counsel.